PROCEPT BioRobotics Corporation - Common Stock (PRCT)
18.28
-0.10 (-0.54%)
NASDAQ· Last Trade: Aug 4th, 11:19 PM EDT
Detailed Quote
Previous Close
18.38
Open
17.57
Bid
17.12
Ask
17.75
Day's Range
17.55 - 18.49
52 Week Range
16.67 - 51.18
Volume
3,732,994
Market Cap
-
PE Ratio (TTM)
-10.69
EPS (TTM)
-1.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,657,863
Chart
About PROCEPT BioRobotics Corporation - Common Stock (PRCT)
Procept Biorobotics Corp is a medical technology company focused on advancing minimally invasive surgical solutions, particularly for the treatment of benign prostate hyperplasia. The company develops innovative robotic-assisted platforms that enhance the precision and effectiveness of procedures, empowering urologists to deliver better patient outcomes while reducing recovery times. Procept aims to transform standard surgical practices through its cutting-edge technology, improving the overall experience for both patients and healthcare providers. Read More
PROCEPT BioRobotics (NASDAQ:PRCT) reported second-quarter revenue growth of 19% year over year while lowering its full-year U.S. procedure outlook, citing softer activity at legacy AquaBeam accounts. Management said newer HYDROS Robotic System accounts continued to show stronger utilization, support
NEW YORK and NEW ORLEANS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NasdaqGM: PRCT), if they purchased the Company’s shares between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
SAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2026.
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) between February 28, 2024 and February 25, 2026, inclusive.
Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against PROCEPT BioRobotics Corporation (PROCEPT) (NASDAQ: PRCT) on behalf of those who purchased or acquired PROCEPT common stock between February 28, 2024 and February 25, 2026, inclusive. The lawsuit is filed in the United States District Court for the Northern District of California and is captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, No. 26-cv-07691 (N.D. Cal.). Investors have until September 22, 2026, to file for lead plaintiff status.
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired PROCEPT BioRobotics Corporation (“PROCEPT” or the “Company”) (NASDAQ: PRCT) securities between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”). PROCEPT investors have until September 22, 2026 to file a lead plaintiff motion.
NEW ORLEANS, July 30, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation (NasdaqGM: PRCT) (“Procept” or the “Company”), if they purchased the Company’s shares between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Levi & Korsinsky, LLP alerts investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a securities class action has been filed on behalf of shareholders who purchased securities between February 28, 2024 and February 25, 2026. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
Law Offices of Howard G. Smith reminds investors of the upcoming September 22, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) securities between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”).
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, both dates inclusive (the “Class Period”), have until September 22, 2026 to seek appointment as lead plaintiff of the Procept class action lawsuit. Captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, No. 26-cv-07691 (N.D. Cal.), the Procept class action lawsuit charges Procept and certain of Procept’s top current and former executive officers with violations of the Securities Exchange Act of 1934.
